Pål Berg‐Hansen

Early High Efficacy Treatment in Multiple Sclerosis Is the Best Predictor of Future Disease Activity Over 1 and 2 Years in a Norwegian Population-Based Registry

Cecilia Smith Simonsen, Heidi Øyen Flemmen, Line Broch et al. · Frontiers in Neurology · 2021 · 104 citations · Full text

Medicine, Neurology, Pharmacotherapy +9

High prevalence of fatigue in contemporary patients with multiple sclerosis

Line Broch, Cecilia Smith Simonsen, Heidi Øyen Flemmen et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 2021 · 69 citations · Full text

Medicine, Internal Medicine, Neurology +16

Genetic variants are major determinants of CSF antibody levels in multiple sclerosis

An Goris, Ine Pauwels, Marte W. Gustavsen et al. · Brain · 2015 · 67 citations · Full text

Life Sciences, Genetics, Neurology +17

The diagnostic value of IgG index versus oligoclonal bands in cerebrospinal fluid of patients with multiple sclerosis

Cecilia Smith Simonsen, Heidi Øyen Flemmen, Trine Lauritzen et al. · Multiple Sclerosis Journal - Experimental Translational and Clinical · 2020 · 65 citations · Full text

Life Sciences, Immunology, Neurology +14

Environmental exposures and the risk of multiple sclerosis investigated in a Norwegian case-control study

Marte W. Gustavsen, Christian M. Page, Stine Marit Moen et al. · BMC Neurology · 2014 · 59 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +17